TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
SUPN

Supernus Pharmaceuticals Inc

Healthcare · Drug Manufacturers - Specialty & Generic

43.30$ -0.2% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Income Statement SUPN
Line item 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
– +110.0% +326.7% -99.7% +657.5% +84.3% +712.1% +915.4% +18.3% +48.9% +40.6% +35.3% -3.9% +32.5% +11.4% +15.1% -8.9% +8.9% +8.6%
– – -2,556,095.8% – – +13.5% -97.4% +421.6% +46.3% +42.3% +26.9% +0.9% +8.5% +214.9% +43.1% +16.2% -3.9% -7.0% -4.3%
– +110.0% +423.3% -71.0% -94.1% +84.3% +637.5% +965.4% +17.0% +49.3% +41.4% +37.1% -4.4% +24.4% +7.9% +14.9% -9.7% +11.5% +10.4%
– +58.1% -3.9% +20.1% -12.9% -23.2% -26.7% +13.6% +48.8% +46.9% +15.9% +79.9% -22.5% +9.9% +19.1% -17.6% +22.9% +18.8% -2.4%
– – +8.5% +9.3% – – +186.0% +40.7% +21.2% +20.3% +23.8% +12.0% +0.9% -44.0% +59.4% +4.2% +116.3% +4.5% -20.4%
– +49.3% -2.4% +18.6% -4.2% +13.2% +66.9% +26.4% +28.5% +25.7% +26.0% +32.9% -8.7% +29.3% +42.3% +27.5% -0.9% -5.1% +35.6%
– – – -1,099.1% – – – – -27.1% +206.9% +83.6% +45.1% +2.9% +16.9% -50.5% -46.4% -111.4% – -145.1%
– +389.5% -98.6% -12.3% +1,643.9% +91.6% +119.6% -28.4% -15.1% +6.7% -69.2% +1,055.0% +25.4% +4.6% -1.4% -69.8% -65.8% -100.0% –
– – – -1,053.9% – – – – -24.7% +236.4% +99.8% +39.3% +5.2% +14.3% -56.6% -17.0% -95.4% +3,434.5% -150.1%
– -40.4% +259.5% -110.5% – – +521.8% -43.2% -76.3% -4,373.2% – -32.7% +18.0% +21.1% -52.6% -99.8% +4,440.6% +1,552.1% -143.7%
– – – -8,461.5% – -182.6% – – -29.5% +550.8% -37.2% +93.8% +1.9% +12.3% -57.9% +13.6% -97.8% +5,512.8% -152.2%
– – – -834.9% – – – – – +160.1% +90.2% +40.7% +19.1% +16.7% -38.6% +18.7% -41.3% +98.0% -76.1%

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?